ParkinsonFranceV1, Main, Exploration, bibRecord, 003C12

Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset

Identifieur interne : 003C12 ( Main/Exploration ); précédent : 003C11; suivant : 003C13

Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset

Auteurs : P. Jenner [Royaume-Uni] ; B.-Y. Zeng [Royaume-Uni] ; L. A. Smith [Royaume-Uni] ; R. K. B. Pearce [Royaume-Uni] ; B. Tel [Royaume-Uni] ; L. Chancharme [France] ; G. Moachon [France]

Source :

Experimental brain research [ 0014-4819 ] ; 2000.

RBID : Pascal:00-0432920

Descripteurs français

Pascal (Inist)
- Neurotoxine, Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro), Trouble moteur, Traitement, Neuroprotecteur, Modafinil, Voie nigrostriatale, Neurone dopaminergique, Antiparkinsonien, Animal, Parkinson maladie, Callithrix jacchus.

English descriptors

KwdEn :
- Animal, Antiparkinson agent, Callithrix jacchus, Dopaminergic neuron, Modafinil, Motor system disorder, Neuroprotective agent, Neurotoxin, Nigrostriatal pathway, Parkinson disease, Treatment.

Abstract

The psychostimulant drug, modafinil, protects rodents against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity, striatal ischemia and partial transection of the nigro-striatal pathway. We now report on the ability of modafinil to reverse motor disability in MPTP-treated common marmosets and to prevent MPTP-induced nigral cell death in this species. In the initial experiments, adult common marmosets were treated with MPTP to produce stable motor deficits. The subsequent administration of modafinil (10, 30 or 100 mg/kg/day, p.o.) produced a dose-dependent reversal of motor disability. In a subsequent experiment, normal common marmosets were concurrently treated with 10, 30 or 100 mg/kg of modafinil once daily by gavage during acute MPTP administration (daily for 5 days), continuing for 2 weeks after the last dose of MPTP. Modafinil dose-dependently prevented the decline in motor activity normally produced by MPTP treatment. MPTP treatment caused a 76% loss of nigral tyrosine-hydroxylase-immunoreactive cells in placebo-treated animals, and this was dose-dependently prevented by modafinil. At the highest dose (100 mg/kg/day) of modafinil, there was no significant loss of tyrosine-hydroxylase-immunoreactive cells in the substantia nigra compared with normal animals. MPTP treatment also reduced striatal dopamine uptake sites by 95%, as measured by specific [³H]-mazindol binding, compared with normal controls. Modafinil treatment dose-dependently reduced the loss of specific [³H]-mazindol binding. Behavioural and morphological evidence in the present study indicate a potential antiparkinsonian and neuroprotective role for modafinil, which may form a new pharmacological approach to the treatment of Parkinson's disease.

Affiliations:

France, Royaume-Uni

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001323
to stream PascalFrancis, to step Curation: 000115
to stream PascalFrancis, to step Checkpoint: 001243
to stream Main, to step Merge: 004280
to stream Main, to step Curation: 003C12

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset</title>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zeng, B Y" sort="Zeng, B Y" uniqKey="Zeng B" first="B.-Y." last="Zeng">B.-Y. Zeng</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smith, L A" sort="Smith, L A" uniqKey="Smith L" first="L. A." last="Smith">L. A. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tel, B" sort="Tel, B" uniqKey="Tel B" first="B." last="Tel">B. Tel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chancharme, L" sort="Chancharme, L" uniqKey="Chancharme L" first="L." last="Chancharme">L. Chancharme</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratoire L. Lafon, Centre de Recherches</s1>
<s2>9470 Maisons-Alfort</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
<wicri:noRegion>Centre de Recherches</wicri:noRegion>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moachon, G" sort="Moachon, G" uniqKey="Moachon G" first="G." last="Moachon">G. Moachon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratoire L. Lafon, Centre de Recherches</s1>
<s2>9470 Maisons-Alfort</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
<wicri:noRegion>Centre de Recherches</wicri:noRegion>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0432920</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0432920 INIST</idno>
<idno type="RBID">Pascal:00-0432920</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001323</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000115</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001243</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001243</idno>
<idno type="wicri:doubleKey">0014-4819:2000:Jenner P:antiparkinsonian:and:neuroprotective</idno>
<idno type="wicri:Area/Main/Merge">004280</idno>
<idno type="wicri:Area/Main/Curation">003C12</idno>
<idno type="wicri:Area/Main/Exploration">003C12</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset</title>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zeng, B Y" sort="Zeng, B Y" uniqKey="Zeng B" first="B.-Y." last="Zeng">B.-Y. Zeng</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Smith, L A" sort="Smith, L A" uniqKey="Smith L" first="L. A." last="Smith">L. A. Smith</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tel, B" sort="Tel, B" uniqKey="Tel B" first="B." last="Tel">B. Tel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disease Research Centre, Division of Pharmacology and Therapeutics, Guy's, King's and St Thomas'School of Biomedical Sciences, King's College, Guy's Campus</s1>
<s2>London SE1 1UL</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>London SE1 1UL</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chancharme, L" sort="Chancharme, L" uniqKey="Chancharme L" first="L." last="Chancharme">L. Chancharme</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratoire L. Lafon, Centre de Recherches</s1>
<s2>9470 Maisons-Alfort</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
<wicri:noRegion>Centre de Recherches</wicri:noRegion>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moachon, G" sort="Moachon, G" uniqKey="Moachon G" first="G." last="Moachon">G. Moachon</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratoire L. Lafon, Centre de Recherches</s1>
<s2>9470 Maisons-Alfort</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
<wicri:noRegion>Centre de Recherches</wicri:noRegion>
<wicri:noRegion>9470 Maisons-Alfort</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Experimental brain research</title>
<title level="j" type="abbreviated">Exp. brain res.</title>
<idno type="ISSN">0014-4819</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Experimental brain research</title>
<title level="j" type="abbreviated">Exp. brain res.</title>
<idno type="ISSN">0014-4819</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Antiparkinson agent</term>
<term>Callithrix jacchus</term>
<term>Dopaminergic neuron</term>
<term>Modafinil</term>
<term>Motor system disorder</term>
<term>Neuroprotective agent</term>
<term>Neurotoxin</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Neurotoxine</term>
<term>Pyridine(1-méthyl-4-phényl-1,2,3,6-tétrahydro)</term>
<term>Trouble moteur</term>
<term>Traitement</term>
<term>Neuroprotecteur</term>
<term>Modafinil</term>
<term>Voie nigrostriatale</term>
<term>Neurone dopaminergique</term>
<term>Antiparkinsonien</term>
<term>Animal</term>
<term>Parkinson maladie</term>
<term>Callithrix jacchus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The psychostimulant drug, modafinil, protects rodents against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity, striatal ischemia and partial transection of the nigro-striatal pathway. We now report on the ability of modafinil to reverse motor disability in MPTP-treated common marmosets and to prevent MPTP-induced nigral cell death in this species. In the initial experiments, adult common marmosets were treated with MPTP to produce stable motor deficits. The subsequent administration of modafinil (10, 30 or 100 mg/kg/day, p.o.) produced a dose-dependent reversal of motor disability. In a subsequent experiment, normal common marmosets were concurrently treated with 10, 30 or 100 mg/kg of modafinil once daily by gavage during acute MPTP administration (daily for 5 days), continuing for 2 weeks after the last dose of MPTP. Modafinil dose-dependently prevented the decline in motor activity normally produced by MPTP treatment. MPTP treatment caused a 76% loss of nigral tyrosine-hydroxylase-immunoreactive cells in placebo-treated animals, and this was dose-dependently prevented by modafinil. At the highest dose (100 mg/kg/day) of modafinil, there was no significant loss of tyrosine-hydroxylase-immunoreactive cells in the substantia nigra compared with normal animals. MPTP treatment also reduced striatal dopamine uptake sites by 95%, as measured by specific [<sup>3</sup>
H]-mazindol binding, compared with normal controls. Modafinil treatment dose-dependently reduced the loss of specific [<sup>3</sup>
H]-mazindol binding. Behavioural and morphological evidence in the present study indicate a potential antiparkinsonian and neuroprotective role for modafinil, which may form a new pharmacological approach to the treatment of Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
<li>Royaume-Uni</li>
</country>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
</noRegion>
<name sortKey="Pearce, R K B" sort="Pearce, R K B" uniqKey="Pearce R" first="R. K. B." last="Pearce">R. K. B. Pearce</name>
<name sortKey="Smith, L A" sort="Smith, L A" uniqKey="Smith L" first="L. A." last="Smith">L. A. Smith</name>
<name sortKey="Tel, B" sort="Tel, B" uniqKey="Tel B" first="B." last="Tel">B. Tel</name>
<name sortKey="Zeng, B Y" sort="Zeng, B Y" uniqKey="Zeng B" first="B.-Y." last="Zeng">B.-Y. Zeng</name>
</country>
<country name="France"><noRegion><name sortKey="Chancharme, L" sort="Chancharme, L" uniqKey="Chancharme L" first="L." last="Chancharme">L. Chancharme</name>
</noRegion>
<name sortKey="Moachon, G" sort="Moachon, G" uniqKey="Moachon G" first="G." last="Moachon">G. Moachon</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C12 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003C12 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:00-0432920
   |texte=   Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset

Antiparkinsonian and neuroprotective effects of modafinil in the mptp-treated common marmoset

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri